Beam makes $120M bet that GuideTx’s tech brings gene editing beyond the liver

Published on:

Base-editing biotech Beam Therapeutics engineered an all-stock buyout of Guide Therapeutics, a startup that finds, in vivo, the lipid nanoparticles that can deliver genetic medicines. Beam said GuideTx’s tech helps it address tissue types throughout the body, not just the liver.

Read more    Source: medcitynews.com

Leave a Reply